The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Meet the Challenge of Primary CNS Vasculitis

Meet the Challenge of Primary CNS Vasculitis

September 1, 2011 • By Carlo Salvarani, MD, Robert D. Brown, Jr., MD, MPH, and Gene G. Hunder, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Infectious agents reported in association with CNS vasculitis include varicella zoster virus, human immunodeficiency virus, treponema pallidum, hepatitis virus C, parvovirus B19, cytomegalovirus, Mycoplasma pneumoniae, B burgdorferi, Mycobacterium tuberculosis, Bartonella, and Rickettsiae.

You Might Also Like
  • A&R Abstracts: CNS Vasculitis
  • Rheumatology Case Report: When Moyamoya Disease Mimicks Primary Central Nervous System Vasculitis
  • A Healthy Skepticism: Researchers Evaluate CNS Manifestations of Rheumatic Disease
Explore This Issue
September 2011

Fungal infections (aspergillosis, mucormycosis, coccidioidomycosis, and candidiasis) and subarachnoid cysticercosis have also been implicated in some cases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

CNS vasculitis has also been observed in antineutrophil cytoplasmic antibody–associated vasculitis and Behçet’s syndrome. It has also been reported, although rarely, in polyarteritis nodosa, Henoch-Schonlein purpura, Kawasaki disease, giant cell arteritis, and Takayasu arteritis.

CNS vasculitis is an uncommon manifestation of neurosystemic lupus erythematosus, rheumatoid arthritis, primary Sjögren’s syndrome, dermatomyositis, and mixed connective tissue disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

PCNSV has been associated with lymphoma, particularly Hodgkin’s disease.

Secondary CNS vasculitis also has been described in patients with neurosarcoidosis, inflammatory bowel disease, graft-versus-host disease, and with the use of some drugs (cocaine, amphetamine, ephedrine, and phenylpropanolamine).

Treatment

There are no randomized clinical trials of the medical management in PCNSV. Therefore, treatment for PCNSV has been derived from therapeutic strategies used to treat other vasculitides, anecdotal reports, and PCNSV cohort studies. The earliest reports suggested a poor prognosis with a fatal outcome in the majority of the cases, and transient or doubtful efficacy of glucocorticoids. In 1983, Cupps et al first found CYC in combination with corticosteroids to be effective in PCNSV.22 The most recent PCNSV cohort studies have described a more favorable course of PCNSV. In a study of 101 patients, a favorable response to glucocorticoids alone or in combination with CYC was achieved in 81% of the cases.1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Glucocorticoid therapy should be initiated as soon as the diagnosis of PCNSV is established. We recommend an initial dose of prednisone of 1 mg/kg/day (or equivalent) as a single or divided dose. If the patient does not respond promptly, CYC should be started. A short course of oral CYC for three to six months can also be considered for PCNSV to induce remission, as in other vasculitis. Intravenous pulses of CYC are probably safer than daily oral therapy, although it is unclear whether the two regimes differ in terms of efficacy in PCNSV. After initial treatment with prednisone and cytoxan, one can consider a lower-risk immunosuppressant such as azathioprine, methotrexate, or mycophenolate mofetil (MMF) for maintenance of remission. A treatment course of 12 to 18 months appears adequate in the majority of cases.

Tumor necrosis factor–α (TNF-α) blockers and MMF have successfully been used to treat patients with PCNSV resistant to glucocorticoids and immunosuppressives.23,24 Anti-CD20 therapy with rituximab has been used successfully in refractory granulomatosis with polyangiitis (Wegener’s) involving the CNS, suggesting a possible role for this drug in treating PCNSV.25

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Conditions, Practice Management, Quality Assurance/Improvement, Vasculitis Tagged With: central nervous system, Diagnostic Criteria, Pathogenesis, patient care, Treatment, VasculitisIssue: September 2011

You Might Also Like:
  • A&R Abstracts: CNS Vasculitis
  • Rheumatology Case Report: When Moyamoya Disease Mimicks Primary Central Nervous System Vasculitis
  • A Healthy Skepticism: Researchers Evaluate CNS Manifestations of Rheumatic Disease
  • Meet the Lumbar Spinal Stenosis Challenge

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)